Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. (Q54550505)

31 May 2018

title

Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. (English)

1 reference

31 May 2018

author name string

Mio Furuya

1

1 reference

31 May 2018

Jun Horiguchi

2

1 reference

31 May 2018

Hiroki Nakajima

3

1 reference

31 May 2018

Yoshikatsu Kanai

4

1 reference

31 May 2018

Tetsunari Oyama

5

1 reference

31 May 2018

publication date

15 December 2011

1 reference

31 May 2018

published in

Cancer Science

1 reference

31 May 2018

volume

103

1 reference

31 May 2018

issue

2

1 reference

31 May 2018

page(s)

382-389

1 reference

31 May 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Triple-negative breast cancer: risk factors to potential targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Clinicopathological characteristics of triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Stratifying triple-negative breast cancer: which definition(s) to use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Activation of system L heterodimeric amino acid exchangers by intracellular substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Functional and molecular characteristics of system L in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

L-leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and molecular identity of the transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Complementation of dominant suppression implicates CD98 in integrin activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

CD98hc (SLC3A2) mediates integrin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Mammary development meets cancer genomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Metabolic transformation in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02151.X

10.1111/J.1349-7006.2011.02151.X

21 January 2018

Identifiers

DOI

1 reference

31 May 2018

1 reference

31 May 2018